JP2004509874A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004509874A5 JP2004509874A5 JP2002529075A JP2002529075A JP2004509874A5 JP 2004509874 A5 JP2004509874 A5 JP 2004509874A5 JP 2002529075 A JP2002529075 A JP 2002529075A JP 2002529075 A JP2002529075 A JP 2002529075A JP 2004509874 A5 JP2004509874 A5 JP 2004509874A5
- Authority
- JP
- Japan
- Prior art keywords
- lower alkyl
- compound
- amino
- formula
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 description 32
- 125000000217 alkyl group Chemical group 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- 125000003282 alkyl amino group Chemical group 0.000 description 11
- -1 tri-substituted phenyl Chemical group 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 125000004414 alkyl thio group Chemical group 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 125000001589 carboacyl group Chemical group 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- ZTJLYUVAFAMUKO-UHFFFAOYSA-N 2-phenylethanesulfonic acid Chemical compound OS(=O)(=O)CCC1=CC=CC=C1 ZTJLYUVAFAMUKO-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 0 C*(*)C*S(Nc1c(-c2ccc(C)cc2)c(O*O*)nc(*)n1)(=O)=O Chemical compound C*(*)C*S(Nc1c(-c2ccc(C)cc2)c(O*O*)nc(*)n1)(=O)=O 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- 125000004468 heterocyclylthio group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- NXGRSEAXZLFVEA-UHFFFAOYSA-N n-[5-(4-chlorophenyl)-6-[2-(5-methoxypyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]-2-thiophen-2-ylethanesulfonamide Chemical compound N1=CC(OC)=CN=C1OCCOC1=NC=NC(NS(=O)(=O)CCC=2SC=CC=2)=C1C1=CC=C(Cl)C=C1 NXGRSEAXZLFVEA-UHFFFAOYSA-N 0.000 description 1
- ULMBSZNPLCEURN-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-2-pyridin-2-ylethanesulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=CN=CC=2)OCCOC=2N=CC(Br)=CN=2)=C1NS(=O)(=O)CCC1=CC=CC=N1 ULMBSZNPLCEURN-UHFFFAOYSA-N 0.000 description 1
- KDBRYGUPPHTMQK-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(4-chlorophenyl)pyrimidin-4-yl]-2-thiophen-2-ylethanesulfonamide Chemical compound C1=CC(Cl)=CC=C1C(C(=NC=N1)OCCOC=2N=CC(Br)=CN=2)=C1NS(=O)(=O)CCC1=CC=CS1 KDBRYGUPPHTMQK-UHFFFAOYSA-N 0.000 description 1
- YRFFAZUVONSXEE-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(4-methylphenyl)pyrimidin-4-yl]-2-phenylethanesulfonamide Chemical compound C1=CC(C)=CC=C1C(C(=NC=N1)OCCOC=2N=CC(Br)=CN=2)=C1NS(=O)(=O)CCC1=CC=CC=C1 YRFFAZUVONSXEE-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0009327 | 2000-09-25 | ||
| PCT/EP2001/009894 WO2002024665A1 (en) | 2000-09-25 | 2001-08-28 | Arylalkane-sulfonamides having endothelin-antagonist activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004509874A JP2004509874A (ja) | 2004-04-02 |
| JP2004509874A5 true JP2004509874A5 (https=) | 2008-11-27 |
Family
ID=8164105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002529075A Ceased JP2004509874A (ja) | 2000-09-25 | 2001-08-28 | 新規なアリールアルカン−スルフォンアミド類 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7091201B2 (https=) |
| JP (1) | JP2004509874A (https=) |
| KR (1) | KR100835770B1 (https=) |
| CN (1) | CN1326841C (https=) |
| AR (1) | AR032896A1 (https=) |
| AT (1) | ATE446289T1 (https=) |
| AU (2) | AU2002212171B2 (https=) |
| BR (1) | BR0114082A (https=) |
| CA (1) | CA2423351C (https=) |
| DE (1) | DE60140263D1 (https=) |
| ES (1) | ES2333409T3 (https=) |
| HU (1) | HUP0303364A3 (https=) |
| IL (1) | IL154364A0 (https=) |
| MX (1) | MXPA03001991A (https=) |
| NO (1) | NO20031332L (https=) |
| NZ (1) | NZ524172A (https=) |
| WO (1) | WO2002024665A1 (https=) |
| ZA (1) | ZA200302292B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| US7482355B2 (en) | 2002-08-24 | 2009-01-27 | Astrazeneca Ab | Pyrimidine derivatives as modulators of chemokine receptor activity |
| SE0301653D0 (sv) * | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| SE0301654D0 (sv) * | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| CN1930135B (zh) | 2004-03-05 | 2011-12-28 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3拮抗剂的二氨基嘧啶 |
| KR101280095B1 (ko) | 2004-08-28 | 2013-09-09 | 아스트라제네카 아베 | 케모킨 수용체 조절제로서의 피리미딘 술폰아미드 유도체 |
| CA2619919C (en) | 2005-09-01 | 2014-04-01 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| WO2007025900A1 (en) | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p3x2/3 modulators |
| CA2620129C (en) | 2005-09-01 | 2014-12-23 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| WO2012151440A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
| CN103864701B (zh) * | 2014-03-10 | 2016-08-24 | 常熟市金申医化制品有限责任公司 | 4-磺胺-5-甲氧基-6-氯嘧啶的制备方法 |
| LT3870574T (lt) | 2018-10-23 | 2023-04-11 | Step Pharma S.A.S. | Aminopirimidino/pirazino dariniai, kaip ctps1 inhibitoriai |
| EP3980410B1 (en) * | 2019-06-04 | 2025-02-19 | Step Pharma S.A.S. | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases |
| ES3044436T3 (en) | 2019-06-04 | 2025-11-26 | Step Pharma S A S | N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2h-pyran-4-carboxamide as a human ctps1 inhibitor for the treatment of proliferative diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1549494A (https=) | 1967-10-31 | 1968-12-13 | ||
| TW394761B (en) | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
| JP2790065B2 (ja) * | 1993-12-17 | 1998-08-27 | 田辺製薬株式会社 | ベンゼンスルホンアミド誘導体及びその製法 |
| US5837708A (en) * | 1994-11-25 | 1998-11-17 | Hoffmann-La Roche Inc. | Sulphonamides |
| US5739333A (en) * | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
| JP3013752B2 (ja) * | 1995-05-16 | 2000-02-28 | 田辺製薬株式会社 | スルホンアミド誘導体 |
| JP3067131B2 (ja) * | 1995-06-16 | 2000-07-17 | 田辺製薬株式会社 | 医薬組成物 |
| WO1997022595A1 (en) * | 1995-12-20 | 1997-06-26 | Yamanouchi Pharmaceutical Co., Ltd. | Arylethenesulfonamide derivatives and drug composition containing the same |
| JP3116347B2 (ja) * | 1996-11-13 | 2000-12-11 | 田辺製薬株式会社 | 医薬組成物 |
| AU8035698A (en) * | 1997-06-19 | 1999-01-04 | Yamanouchi Pharmaceutical Co., Ltd. | Substituted lower alkanesulfonamide derivatives and pharmaceutical composition containing the same |
| JPH11343239A (ja) * | 1998-03-31 | 1999-12-14 | Tanabe Seiyaku Co Ltd | 排尿障害の予防・治療剤 |
-
2001
- 2001-08-28 JP JP2002529075A patent/JP2004509874A/ja not_active Ceased
- 2001-08-28 CN CNB01815896XA patent/CN1326841C/zh not_active Expired - Fee Related
- 2001-08-28 KR KR1020037003599A patent/KR100835770B1/ko not_active Expired - Fee Related
- 2001-08-28 WO PCT/EP2001/009894 patent/WO2002024665A1/en not_active Ceased
- 2001-08-28 CA CA2423351A patent/CA2423351C/en not_active Expired - Fee Related
- 2001-08-28 US US10/381,568 patent/US7091201B2/en not_active Expired - Fee Related
- 2001-08-28 AU AU2002212171A patent/AU2002212171B2/en not_active Ceased
- 2001-08-28 ES ES01980288T patent/ES2333409T3/es not_active Expired - Lifetime
- 2001-08-28 IL IL15436401A patent/IL154364A0/xx unknown
- 2001-08-28 AT AT01980288T patent/ATE446289T1/de active
- 2001-08-28 HU HU0303364A patent/HUP0303364A3/hu unknown
- 2001-08-28 AU AU1217102A patent/AU1217102A/xx active Pending
- 2001-08-28 MX MXPA03001991A patent/MXPA03001991A/es active IP Right Grant
- 2001-08-28 DE DE60140263T patent/DE60140263D1/de not_active Expired - Lifetime
- 2001-08-28 NZ NZ524172A patent/NZ524172A/en unknown
- 2001-08-28 BR BR0114082-5A patent/BR0114082A/pt not_active Application Discontinuation
- 2001-09-24 AR ARP010104490A patent/AR032896A1/es not_active Application Discontinuation
-
2003
- 2003-03-24 NO NO20031332A patent/NO20031332L/no not_active Application Discontinuation
- 2003-03-24 ZA ZA200302292A patent/ZA200302292B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004517855A5 (https=) | ||
| JP2004509874A5 (https=) | ||
| CA2431675A1 (en) | Novel sulfamides and their use as endothelin receptor antagonists | |
| JP5827327B2 (ja) | リン酸輸送を阻害する化合物及び方法 | |
| PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
| SE0102764D0 (sv) | Compounds | |
| JP2017149769A5 (https=) | ||
| RU2316553C2 (ru) | Производные пиперидина, фармацевтическая композиция на их основе и применение | |
| US20170273980A1 (en) | Benzyl substituted indazoles as bub1 inhibitors | |
| EA200702641A1 (ru) | Препараты наночастиц мезилата иматиниба | |
| JP2021534124A5 (https=) | ||
| JP2004531549A5 (https=) | ||
| JP2010526079A5 (https=) | ||
| JP2019501195A5 (ja) | 腫瘍を処置するための抗ｅｇｆｒ組み合わせ | |
| US20170305882A1 (en) | Benzyl substituted indazoles as bub1 kinase inhibitors | |
| WO2004030627A2 (en) | Synergistic methods and compositions for treating cancer | |
| JP2005533827A5 (https=) | ||
| CA2460160A1 (en) | Thiazolyl substituted aminopyrimidines as plant protection agents | |
| JP2014511869A5 (https=) | ||
| JP2004534850A5 (https=) | ||
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| CA2423351A1 (en) | Novel arylalkane-sulfonamides | |
| RU2003103780A (ru) | Соединения фенилпиридазина и содержащие их лекарственные средства | |
| JP2004504385A5 (https=) | ||
| JP2020534374A5 (https=) |